Connect with us


HealthPlus Fertility: first in the UAE to offer Future Fertility’s AI-powered oocyte assessment tech

Unlike the traditional approach to estimating egg quality, Future Fertility’s software considers individual variability



HealthPlus Fertility, a prominent fertility clinic network in the United Arab Emirates, is proud to announce its strategic partnership with Future Fertility, the global leader in clinically validated AI-powered fertility solutions.

This partnership marks a significant milestone in the UAE’s fertility landscape, making HealthPlus Fertility the first network of clinics in the region to offer Future Fertility’s personalised oocyte quality reports to its patients.

Services will be available at the clinics in Dubai and Abu Dhabi from October 2023.

Future Fertility’s software leverages artificial intelligence (AI) to analyse oocyte images and provide insight into the reproductive potential of each egg.

Unlike the traditional approach to estimating egg quality, which relies on a patient’s age group and the number of mature eggs retrieved, Future Fertility‘s software considers individual variability. This valuable information empowers patients to make more informed decisions along the fertility journey and enables providers to better optimize treatment plans.

VIOLET, for egg freezing patients, and MAGENTA, for IVF-ICSI patients, are already in use in more than 15 countries, revolutionising the way fertility specialists and embryologists assess egg quality.

HealthPlus Fertility, known for its commitment to excellence in reproductive healthcare, views this partnership as a significant value proposition for its patients.

“At HealthPlus Fertility, we are dedicated to offering the latest advancements in fertility care. Partnering with Future Fertility allows us to deliver tailored insights that enhance patient experiences and have the potential to improve outcomes,” says Jules McDonald, director of clinical operations at HealthPlus Fertility.

Future Fertility’s CEO Christy Prada expressed excitement about increasing access to this technology and partnering with HealthPlus to bring such services to the region.

“We are thrilled that our oocyte quality reports are now available to fertility patients in the UAE. Our goal has always been to empower patients and their providers with personalised insights, enabling them to make informed decisions.

“We couldn’t be more pleased to partner with a highly distinguished and accredited network like HealthPlus, who are renowned for their impressive commitment to quality and patient care.”

Dr Walid Sayed, consultant reproductive endocrinology and infertility and medical director at HealthPlus Fertility, also highlighted the scientific advantages of Future Fertility’s tools, noting: “Until now, embryologists faced challenges in scoring oocyte quality manually, as there has been no validated, agreed-upon oocyte scoring system.

“Future Fertility’s technology bridges this gap, providing a consistent and objective approach to assessing oocyte quality.”

This collaboration comes at a time when the IVF and egg freezing market in the UAE is experiencing remarkable growth.

According to market research, the UAE IVF market is projected to expand at a compound annual growth rate of around 14.12 per cent from 2022 to 2027. This growth is driven by various factors, including an increase in infertility cases and the rising popularity of IVF treatments.

Additionally, the government’s support and changing cultural attitudes have fuelled demand for fertility treatments. Notably, legislation changes in 2021 allowed patients to undergo egg freezing for both medical and social reasons.

The new regulation also allowed human embryos to be frozen for up to five years.

HealthPlus Fertility and Future Fertility are excited to embark on this new partnership and look forward to collaborating on scientific studies that explore novel applications for AI technology and its role in enhancing fertility treatments in the UAE.

Together, they aim to bring innovative and cutting-edge solutions to patients, empowering them on their fertility journey.


AI start-up launches out of stealth in bid to ‘transform’ women’s health



Cercle, an AI San Francisco start-up focused on advancing women’s healthcare, has launched out of stealth.

Cercle says it aims to harmonise and transform “the raw and fragmented” medical data into accurate insights that help improve patient outcomes.

Its tech platform, Cercle Biomedical Graph, claims to be the only one of its kind harnessing and connecting anonymised biomedical and genomics data points drawn from healthcare clinics and research labs around the world.

The company argues that the data insights collected through its platform could have the potential to speed up medical discoveries in the pharmaceutical and research fields, accelerate precision medicine and treatments and help clinics improve the efficiency and effectiveness of medical care.

“We believe a healthy life is a right, not a privilege,” explains Juan Carlos Riveiro, co-founder and CEO of Cercle.

“Instead of continuing to collect cobwebs, the world’s medical data should be leveraged to generate groundbreaking data-driven insights at speed and scale. These insights can catalyse medical breakthroughs and guide practitioners and patients to better healthcare decisions.

“That’s the founding mission behind Cercle, to personalise and contextualise biomedical and genomics information so women can make better, more informed health decisions,” he adds.

“We are starting with the fertility market, and our long-term goal is to radically improve healthcare equity for women across the world.”

Kate Devine, medical director and chief research officer at US Fertility who has partnered with Cercle, says: “USF’s partnership with Cercle has helped us organise unstructured, de-identified clinical data for analysis. This is optimising our research and internal quality assurance capabilities – maximising accuracy, completeness, and efficiency.

“As a field, fertility medicine has dramatically improved and matured to the point of high success over a short time period.

“My hope is that AI tools will help us cross the next threshold of success in terms of patient outcomes, patient experience and optimising efficiency so that we can expand access to fertility care to everyone who needs it.”

Marco Barbierato, managing director of Eurofins Genoma who has also partnered with Cercle, says: “Eurofins Genoma is optimistic about the use of AI in healthcare.

“The technology that Cercle leverages within its biomedical graph allows for efficient insights that clinics Eurofins Genoma serves did not have access to previously.

“This will support the genetics industry to take a step towards contributing to improving overall health outcomes.”

Continue Reading


Federally funded non-profit approves US$80.5m for maternal health research

The funding is hoped to help researchers evaluate multicomponent interventions that address healthcare and social determinants of health



A federally funded non-profit has approved US$80.5m for research tackling the social and clinical care factors that contribute to maternal health inequities.

The Patient-Centered Outcomes Research Institute (PCORI) has awarded the funding to support four comparative clinical effectiveness research (CER) studies focused on the healthcare and social factors that contribute to inequities in maternal morbidity and mortality. The trials are among 30 CER studies and related projects recently approved for PCORI funding.

The four CER studies will focus on populations disproportionately experiencing adverse maternal health outcomes, including Black people, Hispanic and Latin American individuals, those living in rural areas and individuals with lower incomes.

The projects aim to evaluate multicomponent interventions that address both healthcare and social determinants of health.

For each study, dual principal investigators from research institutions and community organisations will co-lead assessments of approaches intended to address the health challenges that impact maternal health in different communities.

“The usual approaches to health research and healthcare have not sufficiently addressed the alarming and worsening national crisis of maternal death and severe illness,” said PCORI executive director Nakela L. Cook.

“Patient-centred comparative clinical effectiveness research that responds to the many challenges concurrently facing pregnant individuals and those who care for them has the capacity to answer questions about which combinations of approaches can best resolve some of these complex maternal healthcare challenges that have for too long defied solutions.”

The studies, Cook said, will be conducted across a broad swath of the United States, including rural and urban areas and states in the Northeast, Midwest, Mid-Atlantic and the South. They will compare a range of practice-level and community- and home-based interventions that address common, frequent challenges facing pregnant individuals and new mothers.

Each of these studies are hoped to generate evidence to inform which approaches work best, for whom and in what circumstances.

Harv Feldman, PCORI deputy executive director for patient-centred research programmes, said: “These funding awards mark an important advancement of PCORI’s longstanding leadership in engaging patients and those who care for them in all aspects of comparative clinical effectiveness research to ensure that results are relevant, useful and impactful.

“We look forward to seeing the impact the studies’ findings will have for maternal health across the United States, particularly among populations that continue to disproportionately experience adverse outcomes.”

Continue Reading


Menopause foundation launches initiative to advance women’s health in midlife

The Women’s Midlife Health Policy Institute is planning to publish a white paper sharing focus and need areas to advance women’s health



The US National Menopause Foundation has launched the Women’s Midlife Health Policy Institute (WMHPI) in an effort to improve research, education and policies related to women’s health in midlife.

In the US almost one and a half million women become menopausal each year. By the year 2025, the number of postmenopausal women worldwide is expected to surpass one billion.

Symptoms, which may include hot flashes, insomnia, anxiety, depression, brain fog, memory loss and genitourinary problems, have a significant impact on women’s quality of life and career growth.

A recent Mayo Clinic study found that 15 per cent of women cut back on hours or missed work entirely due to their symptoms, costing them about US$1.8bn a year in lost wages.

“Despite the prevalence and impact of menopause, there is a lack of research, education and resources dedicated to addressing menopause-related health issues and many women feel underserved and unsupported in navigating this life stage,” said Claire Gill, founder and president of the National Menopause Foundation.

According to the Study of Women’s Health Across the Nation (SWAN), which began in 1994, there are racial and ethnic differences with respect to menopausal symptoms and risk for diseases that impact women at a higher rate postmenopausal.

Black women are more likely to report heavy bleeding, have hysterectomies and have higher rates of vasomotor symptoms, known as hot flashes.

Hispanic women develop metabolic syndrome, type 2 diabetes, anxiety, depression and VMS while non-Hispanic Caucasian women have the greatest incident of low bone density.

The WMHPI aims to bring together women’s health advocacy stakeholders, thought leaders and clinicians to “uncover” opportunities for a shared policy agenda and action plan.

The institute is planning to create a white paper sharing focus and need areas to advance women’s health in midlife.

Gill, National Menopause Foundation president, said: “The WMHPI will coordinate a collective policy agenda that amplifies the needs of women at midlife and targets united action among stakeholders to inspire policy that can have a systemic impact on improving women’s health.”

Continue Reading


Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.